82 related articles for article (PubMed ID: 24239883)
21. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
22. Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.
Chauvin L; Goupille C; Blanc C; Pinault M; Domingo I; Guimaraes C; Bougnoux P; Chevalier S; Mahéo K
Biochim Biophys Acta; 2016 Apr; 1861(4):380-90. PubMed ID: 26821209
[TBL] [Abstract][Full Text] [Related]
23. Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKKα-Akt-FKHR signaling cascade.
Weng HY; Hsu MJ; Chen CC; Chen BC; Hong CY; Teng CM; Pan SL; Chiu WT; Lin CH
Eur J Pharmacol; 2013 Jan; 698(1-3):103-9. PubMed ID: 23123054
[TBL] [Abstract][Full Text] [Related]
24. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
Ding H; Sun Y; Hou Y; Li L
Urol Oncol; 2014 Jul; 32(5):720-6. PubMed ID: 24837011
[TBL] [Abstract][Full Text] [Related]
25. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
26. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
Song R; Harris LD; Pettaway CA
Prostate; 2010 May; 70(6):571-83. PubMed ID: 19938012
[TBL] [Abstract][Full Text] [Related]
27. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis.
García S; Mera A; Gómez-Reino JJ; Conde C
Rheumatology (Oxford); 2009 May; 48(5):483-9. PubMed ID: 19228791
[TBL] [Abstract][Full Text] [Related]
29. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells.
Jin S; Pang RP; Shen JN; Huang G; Wang J; Zhou JG
Apoptosis; 2007 Jul; 12(7):1317-26. PubMed ID: 17333316
[TBL] [Abstract][Full Text] [Related]
30. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.
Kato T; Fujita Y; Nakane K; Mizutani K; Terazawa R; Ehara H; Kanimoto Y; Kojima T; Nozawa Y; Deguchi T; Ito M
Cytokine; 2013 Oct; 64(1):251-7. PubMed ID: 23876400
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Sakai I; Miyake H; Terakawa T; Fujisawa M
Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
33. Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication.
Ko HL; Ng HJ; Goh EH; Ren EC
J Viral Hepat; 2013 Sep; 20(9):658-65. PubMed ID: 23910651
[TBL] [Abstract][Full Text] [Related]
34. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.
Yang M; Liu L; Xie M; Sun X; Yu Y; Kang R; Yang L; Zhu S; Cao L; Tang D
Autophagy; 2015; 11(2):214-24. PubMed ID: 25607248
[TBL] [Abstract][Full Text] [Related]
35. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
37. Long‑term exposure to leptin enhances the growth of prostate cancer cells.
Noda T; Kikugawa T; Tanji N; Miura N; Asai S; Higashiyama S; Yokoyama M
Int J Oncol; 2015 Apr; 46(4):1535-42. PubMed ID: 25625287
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression.
Elser M; Borsig L; Hassa PO; Erener S; Messner S; Valovka T; Keller S; Gassmann M; Hottiger MO
Mol Cancer Res; 2008 Feb; 6(2):282-90. PubMed ID: 18314489
[TBL] [Abstract][Full Text] [Related]
40. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Pinton G; Manente AG; Murer B; De Marino E; Mutti L; Moro L
J Cell Mol Med; 2013 Feb; 17(2):233-41. PubMed ID: 23301673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
